DUNEDIN, New Zealand and HERSHEY, Pa., Oct. 16, 2013 /PRNewswire/ -- Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider network in the United States, to make Cxbladder available to an additional 40 million Americans.(Logo: http://photos.prnewswire.com/prnh/20131015/MM98246LOGO) The agreement with FedMed Inc has been finalised with Pacific Edge's subsidiary in the USA, Pacific Edge Diagnostics USA (PED USA). The agreement provides FedMed's contracted insurance carriers, third party administrators, health and welfare funds, and self-insured health plans with access to Cxbladder. More than 40 million Americans have access to FedMed's National Provider Network of over 550,000 physicians, 4,000 hospitals and 60,000 ancillary care providers nationwide. Pacific Edge Chief Executive Officer, David Darling said, "This agreement is further recognition for Cxbladder and its ability to enable clinicians to detect urothelial carcinomas, including cancers of the bladder, from a small urine sample. Combined with the simple to use Urine Sampling System, the Cxbladder technology makes detection of bladder cancer a more effective proposition for both clinicians and patients alike." CEO of PED USAJackie Walker said, "We are enthusiastic about the continued market acceptance of our Cxbladder test for bladder cancer detection.The Cxbladder proposition as a quick, cost effective, non-invasive and highly accurate cancer detection test is particularly appealing to US healthcare professionals, patients, and insurers who can see its positive benefits. This is a big step forward for Cxbladder and further supports our direct marketing efforts to clinicians and cancer patients." Negotiations are underway with other provider networks and insurers as well as integrated health systems, Medicare and Medicaid.